
CAS 2169919-21-3
:Formel:C32H47FN6O4S
InChl:InChI=1S/C32H47FN6O4S/c1-5-39(23(3)4)31(40)27-17-25(33)9-12-28(27)43-29-18-34-22-35-30(29)38-20-32(21-38)13-15-37(16-14-32)19-24-7-10-26(11-8-24)36-44(41,42)6-2/h9,12,17-18,22-24,26,36H,5-8,10-11,13-16,19-21H2,1-4H3
InChI Key:FRVSRBKUQZKTOW-UHFFFAOYSA-N
SMILES:CCN(C(C)C)C(=O)C1=C(C=CC(=C1)F)OC2=CN=CN=C2N3CC4(C3)CCN(CC4)CC5CCC(CC5)NS(=O)(=O)CC
Filtern nach
Reinheitsanteil
0
100
|
0
|
50
|
90
|
95
|
100
6 Produkte gefunden.
- Niedrigster Preis
- Höchster Preis
- Niedrigste Reinheit
- Höchste Reinheit
- Schnellste Lieferung
Revumenib
CAS:Revumenib (SNDX-5613) is a potent and selective oral inhibitor of menin-KMT2A interaction.Cost-effective and quality-assured.Formel:C32H47FN6O4SReinheit:99.12% - 99.97%Farbe und Form:Yellow SolidMolekulargewicht:630.817Revumenib
CAS:N-Ethyl-2-((4-(7-((trans-4-(ethylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamideFormel:C32H47FN6O4SReinheit:98%Molekulargewicht:630.82SNDX-5613
CAS:Revumenib, also known as SNDX-5613, is a potent and selective inhibitor of the interaction between menin and the lysine methyltransferase 2A (KMT2A). In recent studies, it has shown promising results in targeting the epigenetic regulator KMT2A, which seems to be involved in certain leukaemia subtypes.Formel:C32H47FN6O4SReinheit:Min. 95%Molekulargewicht:630.8 g/mol






